REGENXBIO (RGNX) to Release Quarterly Earnings on Thursday

REGENXBIO (NASDAQ:RGNX) is anticipated to issue its quarterly earnings data after the market closes on Thursday, March 13th. Analysts expect the company to announce earnings of ($1.19) per share and revenue of $23.70 million for the quarter. Parties interested in listening to the company’s conference call can do so using this link.

REGENXBIO Stock Up 1.7 %

REGENXBIO stock opened at $6.11 on Wednesday. The company has a fifty day simple moving average of $7.42 and a 200-day simple moving average of $9.15. The firm has a market capitalization of $302.72 million, a price-to-earnings ratio of -1.21 and a beta of 1.35. REGENXBIO has a 52-week low of $5.62 and a 52-week high of $23.33.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the stock. Royal Bank of Canada reaffirmed an “outperform” rating and set a $30.00 price objective on shares of REGENXBIO in a research note on Tuesday, January 21st. StockNews.com upgraded REGENXBIO from a “sell” rating to a “hold” rating in a research report on Friday, March 7th. Raymond James began coverage on REGENXBIO in a research report on Friday, February 7th. They set an “outperform” rating and a $27.00 price objective on the stock. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of REGENXBIO in a research note on Wednesday, January 15th. Finally, The Goldman Sachs Group downgraded REGENXBIO from a “buy” rating to a “neutral” rating and cut their target price for the stock from $38.00 to $14.00 in a research note on Tuesday, February 11th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $33.88.

About REGENXBIO

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.